VRTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.18B

+9.35%

5.172

+29.94%

3.14B

+13.42%

4.833

+19.05%

3.20B

+8.01%

4.958

+9.69%

Estimates Revision

The market is revising Downward the revenue expectations for Vertex Pharmaceuticals Incorporated (VRTX) for FY2025, with the revenue forecasts being adjusted by -0.05% over the past three months. During the same period, the stock price has changed by 13.21%.

Revenue Estimates for FY2025

Revise Downward

-0.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.77%

In Past 3 Month

Stock Price

Go Up

+13.21%

In Past 3 Month

22 Analyst Rating

Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 482.53 USD with a low forecast of 401.00 USD and a high forecast of 575.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

8 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

401.00

Averages

482.53

High

575.00

Current: 0.000

Low

401.00

Averages

482.53

High

575.00

Wolfe Research

Peer Perform -> Outperform

upgrade

2026-01-06

New

Reason

Wolfe Research

Price Target

2026-01-06

New

upgrade

Peer Perform -> Outperform

Reason

Wolfe Research upgraded Vertex Pharmaceuticals to Outperform from Peer Perform.

UBS

Michael Yee

Buy

downgrade

$546 -> $535

2026-01-06

New

Reason

UBS

Michael Yee

Price Target

$546 -> $535

2026-01-06

New

downgrade

Buy

Reason

UBS analyst Michael Yee assumed coverage of Vertex Pharmaceuticals with a Buy rating with a price target of $535, down from $546. The firm believes the risk/reward is attractive here given the pullback in 2025 which sets up well for lots of data readouts for 2026-2027. The company is in a strong position given its core cystic fibrosis business has no patent loss-of-exclusivity until at least 2037 and beyond with a significant barrier to entry and no real competitive threat on the horizon, the analyst tells investors in a research note.

Leerink

Outperform

maintain

$456 -> $525

2025-12-29

Reason

Leerink

Price Target

$456 -> $525

2025-12-29

maintain

Outperform

Reason

Leerink raised the firm's price target on Vertex Pharmaceuticals to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company's revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models.

Morgan Stanley

Overweight

maintain

$516 -> $564

2025-12-05

Reason

Morgan Stanley

Price Target

$516 -> $564

2025-12-05

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Vertex Pharmaceuticals to $564 from $516 and keeps an Overweight rating on the shares after having hosted a lab tour and analyst meeting with the company's CEO and kidney disease program leads. The firm refreshed its model following the recent pricing disclosure for Otsuka's Voyxact as it raises its annual WAC price estimate for pipeline drugs Pove to $390,000 from $250,000.

Morgan Stanley

Terence Flynn

Equal Weight -> Overweight

upgrade

$438 -> $516

2025-12-03

Reason

Morgan Stanley

Terence Flynn

Price Target

$438 -> $516

2025-12-03

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley analyst Terence Flynn upgraded Vertex Pharmaceuticals to Overweight from Equal Weight with a price target of $516, up from $438. The firm is taking a more positive stance on the company's kidney franchise pipeline, including Pove and Inaxaplin. If the drugs are successful in Phase 3, with key data coming in 2026, they will accelerate Vertex's earnings and revenue growth and drive diversification away from cystic fibrosis, the analyst tells investors in a research note.

Scotiabank

NULL -> Outperform

initiated

$495

2025-11-12

Reason

Scotiabank

Price Target

$495

2025-11-12

initiated

NULL -> Outperform

Reason

Scotiabank initiated coverage of Vertex Pharmaceuticals with an Outperform rating and $495 price target.

Valuation Metrics

The current forward P/E ratio for Vertex Pharmaceuticals Inc (VRTX.O) is 22.55, compared to its 5-year average forward P/E of 187.14. For a more detailed relative valuation and DCF analysis to assess Vertex Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

187.14

Current PE

22.55

Overvalued PE

782.12

Undervalued PE

-407.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.51

Current EV/EBITDA

16.66

Overvalued EV/EBITDA

46.67

Undervalued EV/EBITDA

-1.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.64

Current PS

8.97

Overvalued PS

10.11

Undervalued PS

7.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 149.17% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VRTX News & Events

Events Timeline

No data

News

7.5

01-07CNBC

Alaska Air Plans to Purchase 105 Boeing 737 Max 10 Jets

9.5

01-06Fool

Palantir Technologies Reports Significant Revenue Growth in AI Market

3.5

01-02Newsfilter

Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032

People Also Watch

Frequently Asked Questions

What is Vertex Pharmaceuticals Inc (VRTX) stock price today?

The current price of VRTX is 469.68 USD — it has decreased -2.99 % in the last trading day.

What is Vertex Pharmaceuticals Inc (VRTX)'s business?

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

What is the price predicton of VRTX Stock?

What is Vertex Pharmaceuticals Inc (VRTX)'s revenue for the last quarter?

Vertex Pharmaceuticals Inc revenue for the last quarter amounts to 3.08B USD, increased 10.99 % YoY.

What is Vertex Pharmaceuticals Inc (VRTX)'s earnings per share (EPS) for the last quarter?

Vertex Pharmaceuticals Inc. EPS for the last quarter amounts to 4.20 USD, increased 4.74 % YoY.

What changes have occurred in the market's expectations for Vertex Pharmaceuticals Inc (VRTX)'s fundamentals?

How many employees does Vertex Pharmaceuticals Inc (VRTX). have?

Vertex Pharmaceuticals Inc (VRTX) has 6100 emplpoyees as of January 09 2026.

What is Vertex Pharmaceuticals Inc (VRTX) market cap?

Today VRTX has the market capitalization of 119.17B USD.